Literature DB >> 1249184

Changes in drug metabolism in children with thyroid disorders.

P Saenger, A B Rifkind, M I New.   

Abstract

The rate of disappearance of antipyrine from the plasma is a useful indicator for the in vivo capacity of mixed function oxidation. The half-life of antipyrine was measured before and after treatment in three hypothyroid and three hyperthyroid children, aged three months to 14 years, in order to examine the effect on drug metabolism of thyroid disorders in children. The half-life of antipyrine decreased in all three hypothyroid subjects and increased in all three hyperthyroid subjects after treatment. The mean half-life decreased from 34.5 h to 8.6 h after treatment of the hypothyroid subjects and increased from 6.1 to 10.1 h after treatment of the hyperthyroid subjects. The mean metabolic clearance rate of antipyrine increased from 11.7 to 25 ml/h in the hyothyroid patients while in the hyperthyroid children there was a decrease from 43 to 25 ml/h. The apparent volume of distribution did not change significantly in the treatment, thus changes in the half-life of antipyrine were most likely attributable to alterations in the metabolic clearance rate of antipyrine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1249184     DOI: 10.1210/jcem-42-1-155

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

2.  The effect of fever on antipyrine metabolism in children.

Authors:  J S Forsyth; T A Moreland; G W Rylance
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

4.  Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog.

Authors:  T Ishizaki; K Tawara
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

5.  Thyroid hormone regulation of heme oxidation in the liver.

Authors:  T J Smith; G S Drummond; I A Kourides; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency.

Authors:  M J Kennedy; D A Davis; N Smith; A Gaedigk; R E Pearce; G L Kearns
Journal:  Clin Pharmacol Ther       Date:  2008-10-08       Impact factor: 6.875

Review 7.  Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.

Authors:  Mj Kennedy
Journal:  Clin Pharmacol Ther       Date:  2008-10-29       Impact factor: 6.875

8.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

9.  Pathophysiological changes that affect drug disposition in protein-energy malnourished children.

Authors:  Kazeem A Oshikoya; Idowu O Senbanjo
Journal:  Nutr Metab (Lond)       Date:  2009-12-01       Impact factor: 4.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.